Literature DB >> 34750787

An Update on the Critical Role of α-Synuclein in Parkinson's Disease and Other Synucleinopathies: from Tissue to Cellular and Molecular Levels.

Iris N Serratos1, Elizabeth Hernández-Pérez2, Carolina Campos3, Michael Aschner4, Abel Santamaría5.   

Abstract

The aggregation of alpha-synuclein (α-Syn) plays a critical role in the development of Parkinson's disease (PD) and other synucleinopathies. α-Syn, which is encoded by the SNCA gene, is a lysine-rich soluble amphipathic protein normally expressed in neurons. Located in the cytosolic domain, this protein has the ability to remodel itself in plasma membranes, where it assumes an alpha-helix conformation. However, the protein can also adopt another conformation rich in cross-beta sheets, undergoing mutations and post-translational modifications, then leading the protein to an unusual aggregation in the form of Lewy bodies (LB), which are cytoplasmic inclusions constituted predominantly by α-Syn. Pathogenic mechanisms affecting the structural and functional stability of α-Syn - such as endoplasmic reticulum stress, Golgi complex fragmentation, disfunctional protein degradation systems, aberrant interactions with mitochondrial membranes and nuclear DNA, altered cytoskeleton dynamics, disrupted neuronal plasmatic membrane, dysfunctional vesicular transport, and formation of extracellular toxic aggregates - contribute all to the pathogenic progression of PD and synucleinopathies. In this review, we describe the collective knowledge on this topic and provide an update on the critical role of α-Syn aggregates, both at the cellular and molecular levels, in the deregulation of organelles affecting the cellular homeostasis and leading to neuronal cell death in PD and other synucleinopathies.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Lewy bodies; Membrane biological interactions; Organelles; Parkinson’s disease; Post-translational modifications; Synucleinopathies; α-Synuclein

Mesh:

Substances:

Year:  2021        PMID: 34750787     DOI: 10.1007/s12035-021-02596-3

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.682


  194 in total

1.  Staging of brain pathology related to sporadic Parkinson's disease.

Authors:  Heiko Braak; Kelly Del Tredici; Udo Rüb; Rob A I de Vos; Ernst N H Jansen Steur; Eva Braak
Journal:  Neurobiol Aging       Date:  2003 Mar-Apr       Impact factor: 4.673

Review 2.  Non-motor symptoms of Parkinson's disease: diagnosis and management.

Authors:  K Ray Chaudhuri; Daniel G Healy; Anthony H V Schapira
Journal:  Lancet Neurol       Date:  2006-03       Impact factor: 44.182

3.  Alpha-synuclein in Lewy bodies.

Authors:  M G Spillantini; M L Schmidt; V M Lee; J Q Trojanowski; R Jakes; M Goedert
Journal:  Nature       Date:  1997-08-28       Impact factor: 49.962

4.  The function of α-synuclein.

Authors:  Jacob T Bendor; Todd P Logan; Robert H Edwards
Journal:  Neuron       Date:  2013-09-18       Impact factor: 17.173

5.  Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia.

Authors:  Laura Parkkinen; Tarja Kauppinen; Tuula Pirttilä; Jaana M Autere; Irina Alafuzoff
Journal:  Ann Neurol       Date:  2005-01       Impact factor: 10.422

6.  Progression and staging of Lewy pathology in brains from patients with dementia with Lewy bodies.

Authors:  Wami Marui; Eizo Iseki; Toshiki Nakai; Satoshi Miura; Masanori Kato; Kenji Uéda; Kenji Kosaka
Journal:  J Neurol Sci       Date:  2002-03-30       Impact factor: 3.181

7.  Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease.

Authors:  Joshua M Milber; Joseph V Noorigian; James F Morley; Helen Petrovitch; Lon White; G Webster Ross; John E Duda
Journal:  Neurology       Date:  2012-11-14       Impact factor: 9.910

Review 8.  Pathogenesis of familial Parkinson's disease: new insights based on monogenic forms of Parkinson's disease.

Authors:  Taku Hatano; Shin-ichiro Kubo; Shigeto Sato; Nobutaka Hattori
Journal:  J Neurochem       Date:  2009-09-24       Impact factor: 5.372

Review 9.  The Synucleinopathies: Twenty Years On.

Authors:  Michel Goedert; Ross Jakes; Maria Grazia Spillantini
Journal:  J Parkinsons Dis       Date:  2017       Impact factor: 5.568

10.  Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance.

Authors:  Laura Parkkinen; Tuula Pirttilä; Irina Alafuzoff
Journal:  Acta Neuropathol       Date:  2008-02-23       Impact factor: 17.088

View more
  5 in total

1.  Oral Mucosa Derived α-Synuclein as a Potential Diagnostic Biomarker for Parkinson's Disease.

Authors:  Yuanchu Zheng; Zhenwei Yu; Jiajia Zhao; Huihui Cai; Zhan Wang; Xuemei Wang; Tao Feng
Journal:  Front Aging Neurosci       Date:  2022-03-28       Impact factor: 5.750

2.  Gene Co-expression Analysis of the Human Substantia Nigra Identifies ZNHIT1 as an SNCA Co-expressed Gene that Protects Against α-Synuclein-Induced Impairments in Neurite Growth and Mitochondrial Dysfunction in SH-SY5Y Cells.

Authors:  Erin McCarthy; Aaron Barron; Noelia Morales-Prieto; Martina Mazzocchi; Cathal M McCarthy; Louise M Collins; Aideen M Sullivan; Gerard W O'Keeffe
Journal:  Mol Neurobiol       Date:  2022-02-17       Impact factor: 5.682

Review 3.  Disease-Modifying Therapies for Multiple System Atrophy: Where Are We in 2022?

Authors:  Victoria Sidoroff; Pam Bower; Nadia Stefanova; Alessandra Fanciulli; Iva Stankovic; Werner Poewe; Klaus Seppi; Gregor K Wenning; Florian Krismer
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

4.  Differential Neuropathology, Genetics, and Transcriptomics in Two Kindred Cases with Alzheimer's Disease and Lewy Body Dementia.

Authors:  Ilaria Palmieri; Tino Emanuele Poloni; Valentina Medici; Susanna Zucca; Annalisa Davin; Orietta Pansarasa; Mauro Ceroni; Livio Tronconi; Antonio Guaita; Stella Gagliardi; Cristina Cereda
Journal:  Biomedicines       Date:  2022-07-13

Review 5.  Monogenic Parkinson's Disease: Genotype, Phenotype, Pathophysiology, and Genetic Testing.

Authors:  Fangzhi Jia; Avi Fellner; Kishore Raj Kumar
Journal:  Genes (Basel)       Date:  2022-03-07       Impact factor: 4.096

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.